Harnessing deep expertise to drive progress
in immuno-oncology & inflammation
At Domain, we are redefining the possibilities in drug discovery and development with a proprietary approach built on over two decades of GPCR expertise. By combining a unique platform, advanced technology and a well-defined process, we deliver therapies designed to address high unmet medical needs with precision and purpose.
Our focus is clear: to develop effective GPCR-targeting therapies that achieve better outcomes for patients
in immuno-oncology and inflammation
Through our innovative approach, we introduce and advance transformative solutions to reshape the immune system, overcome treatment resistance, and combat inflammation at its source, addressing critical gaps where current treatments fall short.
Leading the way in GPCR-targeting therapies: Our proven framework for success
Our approach to therapy development is driven by a deep biological understanding of GPCR targets at each stage of the process. From identifying critical GPCRs to advancing therapies through clinical development, this approach is focused on improving therapeutic efficacy, making it particularly valuable in addressing unmet medical needs in complex diseases like cancer and inflammatory conditions.
The key elements of our approach include:
Decoding complex GPCR pharmacology: Leveraging our proven scientific expertise, we identify and validate GPCRs involved in essential biological processes within immune and inflammatory pathways. This foundational work ensures a strategic focus on the most impactful targets.
bioSens-All® technology: Our proprietary platform provides detailed analyses of molecule interaction with GPCRs and modulation of signaling pathways. This enables the precise design of highly effective small molecules and biologics optimized for therapeutic success.
Biomarker-driven development: Biomarkers and disease insights are fully integrated into our drug discovery and development process which enables us to design therapies suited to the most relevant patient groups and disease subtypes. This ensures that we advance only the most promising candidates into clinical development.
Through this focused and expert-driven approach, we continually grow our pipeline with highly differentiated drug candidates and set new benchmarks for addressing significant medical needs.
Creating transformative therapies in immuno-oncology & inflammation
GPCRs play a central role in immune regulation, making them highly valuable targets for addressing critical challenges in immuno-oncology and inflammation.
At Domain, we leverage our proprietary approach founded on a unique platform and unparalleled expertise to identify and advance GPCR assets linked to immunosurveillance mechanisms and inflammatory pathways. These discoveries form the backbone of our robust pipeline of breakthrough therapies, distinguished by their unique biological mechanisms and potential to address significant unmet medical needs, particularly in areas of untapped therapeutic potential.
Our development process integrates a deep understanding of disease biology, patient needs, and clinical applications at every stage
Building on this deep understanding of GPCR biology, our innovative approach focuses on targeting GPCRs that regulate immune cell activity and the tumor microenvironment, reshaping the immune system to effectively combat cancer and improving patient responses in immuno-oncology.
In the field of inflammation, our unmatched knowledge of GPCRs allows us to design therapies that disrupt harmful inflammatory processes and restore balance, tackling diseases with limited treatment options.
By combining rigorous research with a tailored therapeutic design, we provide novel and actionable solutions that aim to transform patient outcomes worldwide.
Scroll back top